These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Daily nicotine patch wear time predicts smoking abstinence in socioeconomically disadvantaged adults: An analysis of ecological momentary assessment data. Ma P; Kendzor DE; Poonawalla IB; Balis DS; Businelle MS Drug Alcohol Depend; 2016 Dec; 169():64-67. PubMed ID: 27776246 [TBL] [Abstract][Full Text] [Related]
29. Effects of Group Psychotherapy, Individual Counseling, Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. Philipsen A; Jans T; Graf E; Matthies S; Borel P; Colla M; Gentschow L; Langner D; Jacob C; Groß-Lesch S; Sobanski E; Alm B; Schumacher-Stien M; Roesler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Heinrich V; Huss M; Kornmann C; Bürger A; Perlov E; Ihorst G; Schlander M; Berger M; Tebartz van Elst L; JAMA Psychiatry; 2015 Dec; 72(12):1199-210. PubMed ID: 26536057 [TBL] [Abstract][Full Text] [Related]
30. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Stead LF; Lancaster T Cochrane Database Syst Rev; 2012 Dec; 12():CD009670. PubMed ID: 23235680 [TBL] [Abstract][Full Text] [Related]
31. Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blind, placebo-controlled trial. Yudkin PL; Jones L; Lancaster T; Fowler GH Br J Gen Pract; 1996 Mar; 46(404):145-8. PubMed ID: 8731618 [TBL] [Abstract][Full Text] [Related]
32. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study. Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533 [TBL] [Abstract][Full Text] [Related]
33. The Fagerström Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Fagerström K; Russ C; Yu CR; Yunis C; Foulds J Nicotine Tob Res; 2012 Dec; 14(12):1467-73. PubMed ID: 22467778 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. Casas M; Rösler M; Sandra Kooij JJ; Ginsberg Y; Ramos-Quiroga JA; Heger S; Berwaerts J; Dejonckheere J; van der Vorst E; Schäuble B World J Biol Psychiatry; 2013 May; 14(4):268-81. PubMed ID: 22106853 [TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan. Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065 [TBL] [Abstract][Full Text] [Related]
36. Using Bayesian hierarchical models for controlled post hoc subgroup analysis of clinical trials: application to smoking cessation treatment in American Indians and Alaska Natives. Shergina E; Richter KP; Makosky Daley C; Faseru B; Choi WS; Gajewski BJ J Biopharm Stat; 2024 Jul; 34(4):513-525. PubMed ID: 37417836 [TBL] [Abstract][Full Text] [Related]
37. Improving the analysis and modeling of substance use. Gorelick DA; McPherson S Am J Drug Alcohol Abuse; 2015; 41(6):475-8. PubMed ID: 26407028 [No Abstract] [Full Text] [Related]
38. Latent Class Dynamic Mediation Model with Application to Smoking Cessation Data. Huang J; Yuan Y; Wetter D Psychometrika; 2019 Mar; 84(1):1-18. PubMed ID: 30607659 [TBL] [Abstract][Full Text] [Related]